Alzheimer’s disease currently affects 1.0% of the population and is expected to triple over the next 30 years.


AD is a chronic neurodegenerative condition with an onset around 60 years of age. It causes progressive cognitive impairments that affect memory, reason, judgement and language. It is currently the most common form of dementia. It is estimated that AD currently affects 1.0% of the US population. It is expected that this number will triple over the next 30 years due to a larger aging population.


Treatment of AD focuses on symptomatic management and improvement of short-term memory impairment. Leading therapies include acetyl cholinesterase inhibitors such as donepezil, and NMDA glutamate receptor antagonists such as memantine.

Unmet Medical Needs

A major issue with AD medication is compliance as treatment options require once or twice daily oral dosing. Patients often cannot adhere to the medication regime due to their lack of short term memory. Studies have shown that switching to a transdermal patch increases adherence to recommended treatment regimens.